ArticleBMC public health2026
Seroprevalence of SARS-CoV-2 in Tanzania: results from a cross-sectional study documenting the Omicron wave in five regions of Tanzania.
Article in BMC public health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors.
Funding
Abstract
backgroundBetween August and October 2021, before the Omicron wave and before COVID-19 vaccines became widely available in Tanzania, two studies estimated that half of the population in Zanzibar and Mwanza in Tanzania had SARS-CoV-2 antibodies. From May 2020 to Dec 2021, Tanzania adopted a very different COVID-19 mitigation strategy with no lockdowns or quarantines and limited community-level COVID-19 testing. We conducted population-based SARS-CoV-2 seroprevalence surveys in five regions of Tanzania between November 2021 and July 2022 to estimate community-level exposure to SARS-CoV-2and vaccine coverage.
methodsRegionally representative cross-sectional serosurveys were progressively conducted via multistage cluster sampling in five regions in Tanzania. Twenty enumeration areas were randomly selected from each region. Seropositivity was determined using the WANTAI SARS-CoV-2 Ab ELISA kit.
resultsWe found that nine out of every ten people living in five geographically dispersed regions in Tanzania had SARS-CoV-2 antibodies despite only 8% vaccination coverage in our sample.
conclusionGiven the high seroprevalence of SARS-CoV-2 in these regions, targeting COVID-19 vaccination efforts to those at greater risk of severe disease may help maximize the public health impact.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.